Drainage Amount for Removal of Thoracostomy Tube (DARTT)

June 19, 2017 updated by: University of California, Davis

Non-inferiority Randomized Trial Evaluating Removal of Thoracostomy Tubes Independent of the Drainage Amount Versus Removal When the Drainage Amount Is Low

The purpose of this study is to determine whether chest tubes can be safely removed without considering how much fluid is draining through the tube.

Study Overview

Detailed Description

Thoracostomy tubes are routinely used to drain the pleural space of fluid and gas to optimize pulmonary mechanics. Clinicians frequently postpone removal of thoracostomy tubes if the drainage from the tube exceeds a specific volume threshold for the prior 24 hours. However, there is substantial variability in the drainage volume threshold that different clinicians use, and no threshold has been established as clearly superior to any other. Removing tubes independently of the drainage volume may result in a greater risk of pleural effusion or pneumothorax requiring an invasive drainage procedure. However, removing tubes independently of the drainage volume might also expedite recovery by allowing earlier removal of the tube, thus diminishing pain and increasing patient mobility.

Thoracostomy tube management practices, including the drainage volume threshold used, may be dissimilar for different types of disease processes, so this study will be restricted to patients who required a thoracostomy tube for treatment of traumatic injury.

Study Type

Interventional

Enrollment (Actual)

280

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Sacramento, California, United States, 95817
        • University of California, Davis, Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Thoracostomy tube in place for <72 hours
  • Age at least 14 years
  • Hospitalized for traumatic injury or elective operation

Exclusion Criteria:

  • Thoracostomy tube already removed from the pleural cavity of interest
  • Mediastinal tubes
  • Death expected within 48 hours
  • Prisoner status
  • Severe congestive heart failure
  • End-stage liver disease
  • End-stage renal disease
  • History of or suspected empyema involving the pleural cavity of interest
  • History of or anticipated need for pleurodesis of the pleural cavity of interest
  • Malignant pleural effusion
  • Pregnancy
  • Previous participation in this study
  • Thoracostomy tube drainage already <2 mL/kg

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 1
No drainage threshold
Removal of the thoracostomy tube independently of the amount of fluid that drained from the tube in the prior 24 hours
Active Comparator: 2
Drainage <2 mL/kg
Removal of the thoracostomy tube only if the drainage from the tube in the prior 24 hours is less than 2 mL/kg of the patient's ideal body weight
Other Names:
  • Standard thoracostomy tube management

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Invasive drainage procedure
Time Frame: Within 60 days
Within 60 days

Secondary Outcome Measures

Outcome Measure
Time Frame
Mortality
Time Frame: 60 days
60 days
Time to thoracostomy tube removal
Time Frame: Within 60 days
Within 60 days
Pulmonary symptoms
Time Frame: 60 days
60 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Garth H Utter, MD MSc, University of California, Davis

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2007

Primary Completion (Actual)

September 1, 2012

Study Completion (Actual)

December 1, 2012

Study Registration Dates

First Submitted

December 14, 2007

First Submitted That Met QC Criteria

December 14, 2007

First Posted (Estimate)

December 18, 2007

Study Record Updates

Last Update Posted (Actual)

June 21, 2017

Last Update Submitted That Met QC Criteria

June 19, 2017

Last Verified

June 1, 2017

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 200715709

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pneumothorax

Clinical Trials on No drainage threshold

Subscribe